Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
7
×
boston blog main
boston top stories
national blog main
7
×
san diego blog main
san diego top stories
7
×
fda
life sciences
biotech
national top stories
clinical trials
new york blog main
new york top stories
akcea therapeutics
alnylam pharmaceuticals
drugs
hereditary transthyretin amyloidosis
inotersen
medical devices
patisiran
san francisco blog main
san francisco top stories
tafamidis
onpattro
pfizer
rna interference
vyndaqel
andrew fire
antibiotics
arvinas
astrazeneca
atrial fibrillation
barry greene
bay state health
biotech ipos
boston scientific
boston university
boulder/denver
boulder/denver blog main
boulder/denver top stories
What
alnylam
drug
fda
medicine
boston
company
device
ipo
make
rna
rnai
startup
time
uses
way
acquire
adding
afternoon
ago
alnylam’s
approve
approved
approves
atrial
awaits
biological
biotechs
brings
business
cells
censinet
chose
close
continues
crossed
cryterion
cyber
deal
decades
decision
Language
unset
Current search:
" national blog main "
×
boston
×
" san diego top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 years ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion